Bin Tean Teh

Title: The Innovative Contributions of Bin Tean Teh

Introduction

Bin Tean Teh is a notable inventor based in Grand Rapids, MI (US). He has made significant contributions to the field of cancer research, particularly in understanding tumor resistance to therapies. His work focuses on identifying biomarkers that can predict treatment outcomes for patients undergoing sunitinib therapy.

Latest Patents

Bin Tean Teh holds a patent titled "IL-8 as a biomarker for sunitinib resistance." This patent outlines a method for determining whether a tumor will be non-responsive to sunitinib therapy. The method involves detecting elevated levels of IL-8 or MMP12 expression in the tumor compared to a control. Tumors with elevated IL-8 or MMP12 levels are likely to be non-responsive to sunitinib. Additionally, the patent describes a method for inhibiting the proliferation or inducing the death of sunitinib-resistant tumor cells by using agents that inhibit IL-8 or MMP12 activity alongside sunitinib. The invention also includes compositions and kits that feature an IL-8 inhibitor or an MMP12 inhibitor combined with sunitinib, along with related treatment methods.

Career Highlights

Bin Tean Teh is affiliated with the Van Andel Research Institute, where he conducts his research. His work has been instrumental in advancing the understanding of cancer treatment resistance, which is a critical area of study in oncology.

Collaborations

He collaborates with esteemed colleagues, including Richard Kahnoski and Dan Huang, to further his research initiatives and enhance the impact of his findings in the scientific community.

Conclusion

Bin Tean Teh's innovative work in identifying biomarkers for sunitinib resistance represents a significant advancement in cancer research. His contributions have the potential to improve treatment strategies for patients facing challenges with current therapies.